Xiao Ting's Form 4 filing
Zenas BioPharma, Inc. (ZBIO) · filed Feb 11, 2025
- Accession no.
- 0001104659-25-011505
- Filed
- Feb 11, 2025
- Trade date
- Feb 7, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $77.6K. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001104659-25-039771 (Apr 28, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Xiao TingCIK 0002035283 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2025 | Common Stock | PPurchaseAcquired | +10,000 | $7.76F1 | +$77,600 | 47,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.